What is Birth Biologic?
Birth Biologic is dedicated to empowering expecting parents with the opportunity to donate life-saving perinatal tissue, including the placenta and umbilical cord, immediately following childbirth. This donated tissue is rich in valuable stem cells, which hold immense potential for treating a range of life-threatening diseases and advancing critical medical research. The company prioritizes the safety and ethical integrity of its donation process, ensuring no adverse effects on the mother or child. Birth Biologic's core mission is to foster medical breakthroughs through responsible perinatal tissue donation, ultimately aiming to improve and save lives.
How much funding has Birth Biologic raised?
Birth Biologic has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
What's next for Birth Biologic?
With the recent influx of substantial expansion capital, Birth Biologic is poised for significant scaling and further development of its life-saving initiatives. This strategic investment at the Series B/C stage suggests a focus on expanding operational capacity, enhancing research collaborations, and potentially broadening its service offerings to reach more expecting parents. The company's commitment to advancing medical treatments through ethical tissue donation is likely to attract further strategic partnerships and financial backing as it continues to mature and solidify its position in the biotech and healthcare sectors.
See full Birth Biologic company page
